Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Coastal cancer care: A blueprint to address the unmet needs through place-based research and policy approaches.

Journal of cancer policy·2026
Same author

[<sup>68</sup>Ga]Ga-PSMA-11 PET/CT for baseline staging of high-risk prostate cancer: A real-world study.

BJUI compass·2026
Same author

Surgery or radiotherapy for early-stage cancer study protocol for an emulated target trial of radical radiotherapy versus radical cystectomy, with either following neoadjuvant chemotherapy, for organ-confined muscle-invasive bladder cancer.

BMJ open·2026
Same author

Patient Perspectives on Approval Speed vs Evidentiary Certainty in US Cancer Drug Approvals.

JAMA network open·2026
Same author

Comparison of quality of life and sexual function after ileal vs. sigmoid orthotopic neobladder reconstruction following nerves, vas deferens, and seminal vesicle-sparing radical cystectomy: A prospective randomized study.

Urologic oncology·2026
Same author

Quality improvement interventions in surgical oncology: systematic review of international studies.

BJS open·2026
Same journal

Next-Generation Checkpoint Combinations: Optimizing PD-(L)1-Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings.

Current oncology reports·2026
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Anal cancer: are we making progress?

Ajay Aggarwal1, Simon Duke, Rob Glynne-Jones

  • 1Radiotherapy Department, Mount Vernon Centre for Cancer Treatment, Northwood, Middlesex, UK.

Current Oncology Reports
|February 2, 2013
PubMed
Summary
This summary is machine-generated.

Recent advances in anal cancer research show chemoradiation remains effective. Novel strategies have not improved outcomes, but intensity-modulated radiotherapy shows promise for reduced toxicity and potential dose escalation.

More Related Videos

Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine
06:14

Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine

Published on: September 19, 2025

Related Experiment Videos

Last Updated: May 14, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine
06:14

Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine

Published on: September 19, 2025

Area of Science:

  • Oncology
  • Gastroenterology

Background:

  • Anal cancer is a rare malignancy with evolving understanding of its molecular biology.
  • Significant progress has been made in prevention, imaging, and treatment strategies over the last three years.

Purpose of the Study:

  • To review recent literature (past 2 years) on anal cancer.
  • To summarize key developments in molecular biology, prevention, imaging, and treatment.
  • To provide an update on the current state of anal cancer management.

Main Methods:

  • Review of randomized phase III trials and recent literature on anal cancer treatment.
  • Evaluation of novel chemoradiation strategies, including neoadjuvant chemotherapy, maintenance chemotherapy, and radiotherapy modifications.
  • Assessment of intensity-modulated radiotherapy (IMRT) feasibility and preliminary outcomes.

Main Results:

  • Standard chemoradiation (CRT) with mitomycin C (MMC) and 5-fluorouracil (5FU) remains the benchmark treatment.
  • Novel neoadjuvant chemotherapy, maintenance chemotherapy, and radiotherapy dose escalation strategies have not improved upon the standard of care.
  • Intensity-modulated radiotherapy (IMRT) demonstrates feasibility with reduced toxicity and potential for dose escalation to tumors and nodal areas, with preliminary data suggesting maintained efficacy.

Conclusions:

  • Current nonsurgical treatment with CRT is highly effective for loco-regional control and anal function preservation.
  • While novel chemoradiation strategies have not surpassed the standard MMC/5FU regimen, IMRT offers a promising approach for improved treatment delivery and potential efficacy enhancement.
  • Continued research and evaluation of advanced radiotherapy techniques are crucial for optimizing anal cancer management.